Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
Featured trial
Study to evaluate HZN-825 in patients with Idiopathic Pulmonary Fibrosis (IPF)

The goal is to determine the efficacy, safety and tolerability for 360 patients with Idiopathic Pulmonary Fibrosis (IPF) assigned to either one of 2 dose regimens of HZN-825 (administered once daily (QD) or twice daily (BID)) or a placebo regimen for 52 weeks. Participants who complete the duration of this …

emphysema
pneumonia
diffusion capacity of the lung for carbon monoxide
  • 10 views
  • 22 Sep, 2022
  • 28 locations
Featured trial
A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment

A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in

  • 1324 views
  • 23 Nov, 2020
  • 1 location
Management of Progressive Disease in Idiopathic Pulmonary Fibrosis (PROGRESSION)

-modifying therapies, pirfenidone and nintedanib, have been approved worldwide. Both drugs reduce the disease progression as measured by progressive decline in forced vital capacity (FVC), with a reduction

  • 23 views
  • 24 Mar, 2022
  • 9 locations
A Phase I Study for Formulation Selection and Subsequent Optimization of Two Different Oral Formulations of Nintedanib in Healthy Male Subjects (Open-label, Randomised, Single-dose Study in Three Parts)

The main objective of this trial is to assess single dose drug exposure of several newly developed formulation prototypes of Nintedanib compared to Ofev® following oral administration.

Accepts healthy volunteers
  • 0 views
  • 17 Sep, 2022
  • 1 location
An Open-label Trial of the Long-term Safety and Tolerability of Nintedanib Per os, on Top of Standard of Care, Over at Least 2 Years, in Children and Adolescents With Clinically Significant Fibrosing Interstitial Lung Disease (InPedILD®-ON)

, InPedILD®) and for people who are between 6 and 17 years old and have fibrosing ILD. This study tests a medicine called nintedanib. Nintedanib is already used to treat different

  • 0 views
  • 18 Sep, 2022
  • 26 locations
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). There is a 48-week randomized treatment phase followed by an optional, open-label extension phase.

idiopathic pulmonary fibrosis
pamrevlumab
diffusion capacity of the lung for carbon monoxide
nintedanib
carbon monoxide
  • 67 views
  • 14 Jul, 2022
  • 103 locations
Trial Of Pembrolizumab And Nintedanib (PEMBIB)

Both anti-angiogenesis and anti PD1 immunotherapy have shown beneficial efficacy in solid tumors and in particular in NSCLC. Therefore it is of interest to investigate whether the combination of these two approaches is tolerable. Moreover, comprehensive pre-clinical and clinical rationale sustain the hypothesis that anti-VEGF could synergize with immunotherapy for …

  • 0 views
  • 27 Jan, 2022
  • 1 location
Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis (NINTECOR)

Currently, there is no approved treatment for COVID-19 in France, either for the acute phase, nor for the late chronic phase. the investigator suggest that nintedanib has the potential to block

  • 0 views
  • 10 May, 2022
  • 1 location
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (NINBOST2018)

This study investigates the safety and tolerability of Nintedanib in patients with bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation. All study

  • 0 views
  • 12 May, 2022
  • 2 locations
The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial

Prospective clinical pilot study for subjects diagnosed with Occupational Progressive Pneumoconiosis. Subjects will be treated with Nintedanib 150mg twice daily for 3 years.

  • 1 views
  • 19 Feb, 2021
  • 1 location